187 related articles for article (PubMed ID: 33334054)
1. Stroma Transcriptomic and Proteomic Profile of Prostate Cancer Metastasis Xenograft Models Reveals Prognostic Value of Stroma Signatures.
Karkampouna S; De Filippo MR; Ng CKY; Klima I; Zoni E; Spahn M; Stein F; Haberkant P; Thalmann GN; Kruithof-de Julio M
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33334054
[TBL] [Abstract][Full Text] [Related]
2. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
[TBL] [Abstract][Full Text] [Related]
5. Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.
La Manna F; De Menna M; Patel N; Karkampouna S; De Filippo MR; Klima I; Kloen P; Beimers L; Thalmann GN; Pelger RCM; Jacinto E; Kruithof-de Julio M
Front Oncol; 2020; 10():1012. PubMed ID: 32656088
[TBL] [Abstract][Full Text] [Related]
6. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
7. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
9. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
Pecqueux C; Arslan A; Heller M; Falkenstein M; Kaczorowski A; Tolstov Y; Sültmann H; Grüllich C; Herpel E; Duensing A; Kristiansen G; Hohenfellner M; Navone NM; Duensing S
Urol Oncol; 2018 Aug; 36(8):365.e15-365.e26. PubMed ID: 29887238
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
11. Distinct mesenchymal cell states mediate prostate cancer progression.
Pakula H; Omar M; Carelli R; Pederzoli F; Fanelli GN; Pannellini T; Van Emmenis L; Rodrigues S; Fidalgo-Ribeiro C; Nuzzo PV; Brady NJ; Jere M; Unkenholz C; Alexanderani MK; Khani F; de Almeida FN; Abate-Shen C; Greenblatt MB; Rickman DS; Barbieri CE; Robinson BD; Marchionni L; Loda M
bioRxiv; 2023 Apr; ():. PubMed ID: 37034687
[TBL] [Abstract][Full Text] [Related]
12. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
Lee YC; Lin SC; Yu G; Zhu M; Song JH; Rivera K; Pappin DJ; Logothetis CJ; Panaretakis T; Wang G; Yu-Lee LY; Lin SH
Oncogene; 2022 Feb; 41(6):757-769. PubMed ID: 34845375
[TBL] [Abstract][Full Text] [Related]
13. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
14. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
[TBL] [Abstract][Full Text] [Related]
15. Stromal factors involved in human prostate cancer development, progression and castration resistance.
Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
[TBL] [Abstract][Full Text] [Related]
16. The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis.
Bonollo F; Thalmann GN; Kruithof-de Julio M; Karkampouna S
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32668821
[TBL] [Abstract][Full Text] [Related]
17. Separation of breast cancer and organ microenvironment transcriptomes in metastases.
Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
Breast Cancer Res; 2019 Mar; 21(1):36. PubMed ID: 30841919
[TBL] [Abstract][Full Text] [Related]
18. Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.
Bahmad HF; Jalloul M; Azar J; Moubarak MM; Samad TA; Mukherji D; Al-Sayegh M; Abou-Kheir W
Front Genet; 2021; 12():652747. PubMed ID: 33841508
[TBL] [Abstract][Full Text] [Related]
19. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
Kang J; La Manna F; Bonollo F; Sampson N; Alberts IL; Mingels C; Afshar-Oromieh A; Thalmann GN; Karkampouna S
Cancer Lett; 2022 Apr; 530():156-169. PubMed ID: 35051532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
